Literature DB >> 17116981

Monitoring and survival of Lactobacillus gasseri SBT2055 in the human intestinal tract.

Hidetoshi Takahashi1, Takashi Fujita, Yutaka Suzuki, Yoshimi Benno.   

Abstract

The monitoring and survival of Lactobacillus gasseri SBT2055 in the human intestinal tract was investigated with seven healthy subjects having a low number of fecal lactobacilli. An increase of fecal lactobacilli (10(3.2-5.2) CFU/g feces) was recognized after ingestion of yogurt with SBT2055 by the subjects. A high positive rate of L. gasseri in fecal lactobacilli detected from the subjects (over 70% at 2nd weeks of feeding) was also observed during the ingestion period using the species-specific PCR system. These findings indicate that the SBT2055 strain in yogurt survived in the human intestinal tract and was recovered from human feces.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116981     DOI: 10.1111/j.1348-0421.2006.tb03862.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  12 in total

1.  Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.

Authors:  Ji Yeon Kim; Yeo Jin Park; Hyo Jin Lee; Min Young Park; Oran Kwon
Journal:  Food Sci Biotechnol       Date:  2017-12-12       Impact factor: 2.391

2.  Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects.

Authors:  Akihiro Ogawa; Toshiya Kobayashi; Fumihiko Sakai; Yukio Kadooka; Yoshihiro Kawasaki
Journal:  Lipids Health Dis       Date:  2015-03-20       Impact factor: 3.876

3.  Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice.

Authors:  Yosuke Nakayama; Tomohiro Moriya; Fumihiko Sakai; Noriko Ikeda; Takuya Shiozaki; Tomohiro Hosoya; Hisako Nakagawa; Tadaaki Miyazaki
Journal:  Sci Rep       Date:  2014-04-10       Impact factor: 4.379

4.  Lactobacillus gasseri SBT2055 induces TGF-β expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine.

Authors:  Fumihiko Sakai; Tomohiro Hosoya; Aiko Ono-Ohmachi; Ken Ukibe; Akihiro Ogawa; Tomohiro Moriya; Yukio Kadooka; Takuya Shiozaki; Hisako Nakagawa; Yosuke Nakayama; Tadaaki Miyazaki
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

5.  Lactobacillus gasseri SBT2055 reduces infection by and colonization of Campylobacter jejuni.

Authors:  Keita Nishiyama; Yasuyuki Seto; Kazuki Yoshioka; Tsutomu Kakuda; Shinji Takai; Yuji Yamamoto; Takao Mukai
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

6.  Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease.

Authors:  R Kobayashi; T Kobayashi; F Sakai; T Hosoya; M Yamamoto; T Kurita-Ochiai
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

7.  Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects.

Authors:  Akihiro Ogawa; Yukio Kadooka; Ken Kato; Bungo Shirouchi; Masao Sato
Journal:  Lipids Health Dis       Date:  2014-02-19       Impact factor: 3.876

8.  Lactobacillus gasseri SBT2055 inhibits adipose tissue inflammation and intestinal permeability in mice fed a high-fat diet.

Authors:  Michio Kawano; Masaya Miyoshi; Akihiro Ogawa; Fumihiko Sakai; Yukio Kadooka
Journal:  J Nutr Sci       Date:  2016-05-30

Review 9.  Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?

Authors:  Ana H A Morais; Thais S Passos; Bruna L L Maciel; Juliana K da Silva-Maia
Journal:  Nutrients       Date:  2020-06-10       Impact factor: 5.717

10.  Study of the In Vitro Antagonistic Activity of Various Single-Strain and Multi-Strain Probiotics against Escherichia coli.

Authors:  Sabina Fijan; Dunja Šulc; Andrej Steyer
Journal:  Int J Environ Res Public Health       Date:  2018-07-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.